Explore immunotherapy discoveries, treatment approvals and milestones.
See Our Breakthroughs
Working to make a difference in the lives of all affected by cancer.
Learn About Our Work
Learn more about this revolutionary cancer treatment.
Understand the Basics
Find clinical trials that match your diagnosis, stage and treatment history.
Meet the CRI scientists committed to the development of immunotherapy.
Day 3 at the 2017 annual meeting of the American Society of Clinical Oncology touched on immunotherapy combinations and the promise of several novel immunotherapies, including anti-IDO1 checkpoint blockade and a personalized, patient-specific vaccine. Other measures of immunotherapy’s effectiveness, such as patient quality of life, were also discussed. Below are some of the most important findings that were revealed today:
Multiple Tumor Types:
Head and Neck Cancer:
Melanoma / Skin Cancers:
Stomach & Gastrointestinal Cancer:
ASCO17: Day 2 Immunotherapy Highlights
Read Previous Article
ASCO17: Days 4 and 5 Immunotherapy Highlights
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
FDA approves new immunotherapy--Yescarta (axicabtagene ciloleucel)--for adult patients with relapsed or refractory non-Hodgkin large B cell lymphoma.
CRI among 12 top-rated cancer charities within a subset of organizations doing good work in breast cancer as well as other forms of cancer.